Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Xtandi Enzalutamide First Line Metastatic Castration-Resistant Prostate Cancer Reimburse with clinical criteria and/or conditions Complete
Xtandi Enzalutamide Metastatic Castration Resistant Prostate Cancer Reimburse with clinical criteria and/or conditions Complete
Xultophy insulin degludec + liraglutide Diabetes mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete
Xydalba dalbavancin Acute bacterial skin and skin structure infections Reimburse with clinical criteria and/or conditions Complete
Xyrem Sodium oxybate Narcolepsy Withdrawn
Xyrem Sodium oxybate Narcolepsy Do not list Complete
Yasmin Drospirenone /ethinyl estradiol Contraceptive, oral List Complete
Yervoy Ipilimumab Advanced Melanoma Reimburse with clinical criteria and/or conditions Complete
Yervoy Ipilimumab First Line Advanced Melanoma Reimburse with clinical criteria and/or conditions Complete
Yescarta axicabtagene ciloleucel Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) Reimburse with clinical criteria and/or conditions Complete